# Combination With Sintilimab and XELOX+Bevacizumab as 1st Line Therapy in RAS-mutant Metastatic Colorectal Cancer

Source: https://onco.cc/trials/nct05171660/  
OnCo record `nct05171660` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of sintilimab, bevacizumab (glioblastoma use), fOLFOX (5-FU, leucovorin, oxaliplatin) and capecitabine in colorectal cancer, run by Second Affiliated Hospital, Zhejiang University, School of Medicine, active but no longer recruiting.

## Summary

Combination With Sintilimab and XELOX+Bevacizumab as 1st Line Therapy in RAS-mutant Metastatic Colorectal Cancer is a phase 3, randomised interventional study registered as NCT05171660 by Second Affiliated Hospital, Zhejiang University, School of Medicine, with a registry enrolment figure of 446 participants, started 2022-02-08 and due to reach its primary completion in 2026-12-30. Interventions recorded: Sintilimab; Bevacizumab; Oxaliplatin; Capecitabine. Conditions listed: Colorectal Cancer Stage IV. Primary outcome: Progression free survival time. Colorectal eligibility wording from the registry: "Metastatic colorectal adenocarcinoma confirmed by histology, metastases cannot be removed". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-24
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT05171660
- Phase: 3
- Setting: A Randomized, Open, Multicenter Phase III Clinical Trial of Combination of Sintilimab Injection (IBI308) and XELOX+Bevacizumab Compared With XELOX+Bevacizumab as 1st Line Therapy of RAS-Mutant Metastatic Colorectal Cancer
- Sponsor: Second Affiliated Hospital, Zhejiang University, School of Medicine
- Enrolled: 446

## Sources

- ClinicalTrials.gov NCT05171660: https://clinicaltrials.gov/study/NCT05171660

## Connected records

- cancers: [Colon cancer (adenocarcinoma of the colon)](https://onco.cc/cancers/colon-cancer/), [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [Platinum agents](https://onco.cc/technologies/platinum/)
- drugs: [Bevacizumab (glioblastoma use)](https://onco.cc/drugs/bevacizumab-glioma/), [Capecitabine](https://onco.cc/drugs/capecitabine/), [FOLFOX (5-FU, leucovorin, oxaliplatin)](https://onco.cc/drugs/folfox/), [Sintilimab](https://onco.cc/drugs/sintilimab/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct05171660.json